Hims & Hers Health (NYSE:HIMS) Lowered to Hold Rating by Wall Street Zen

Hims & Hers Health (NYSE:HIMS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

A number of other research firms have also weighed in on HIMS. Citigroup reissued a "sell" rating and set a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Piper Sandler reissued a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average target price of $38.00.

Hims & Hers Health Price Performance

HIMS stock opened at $56.44 on Friday. The company has a 50 day moving average price of $42.23 and a 200 day moving average price of $37.13. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock has a market capitalization of $12.63 billion, a PE ratio of 128.28 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS. As a group, equities analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total transaction of $798,976.97. Following the sale, the insider now directly owns 209,661 shares of the company's stock, valued at $7,193,468.91. This represents a 10.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the transaction, the chief executive officer now owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. This trade represents a 42.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 617,367 shares of company stock valued at $25,227,888 over the last three months. 13.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently bought and sold shares of HIMS. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Nuveen LLC purchased a new position in shares of Hims & Hers Health during the 1st quarter worth approximately $58,403,000. Finally, Yong Rong HK Asset Management Ltd purchased a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.